Safety, efficacy and development of resistance under the new protease inhibitor lopinavir/ritonavir: 48-Week results

Infection

Volumn 32, Issue 2, 2004, Pages 82-88

  Voigt, E ^a   Wasmuth, J C ^a   Vogel, M ^a   Mauss, S ^b   Schmutz, G ^b   Kaiser, R ^c   Rockstroh, J K ^a  

^a UNIVERSITY OF BONN   (Germany)

^b Private Practice   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMINO ACID; AMPRENAVIR; CHOLESTEROL; INDINAVIR; LOPINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TRIACYLGLYCEROL;

ACUTE PANCREATITIS; ADULT; ADVERSE DRUG REACTION; AGED; AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; GENE MUTATION; GENOTYPE; GERMANY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MULTICENTER STUDY; OPEN STUDY; OUTCOMES RESEARCH; PROSPECTIVE STUDY; RISK FACTOR; SEQUENCE ANALYSIS; TREATMENT FAILURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PHARMACOGENETICS; PROBABILITY; PROSPECTIVE STUDIES; PYRIMIDINONES; RISK ASSESSMENT; RITONAVIR; RNA, VIRAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIRAL LOAD;

EID: 1842451941     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-004-3059-3     Document Type: Article

References (20)

1. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, Markowitz M, Chernyavskiy T, Niu P, Lyons N, Hsu A, Granneman GR, Ho DD, Boucher CA, Leonard JM, Norbeck DW, Kempf DJ: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996; 2: 760-766.
2. Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F, Brun-Vezinet F: Mechanisms of virological failure in previously untreated HIV-infected patients from a trial of induction - maintenance therapy. JAMA 2000; 283: 205-211.
3. Hertogs K, Bloor S, Kemp SD, Van den Eynde C, Alcorn TM, Pauwels R, Van Houtte M, Staszewski S, Miller V, Larder BA: Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 2000; 14: 1203-1210.
4. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA, Sun E, Pizzuti D, Plattner JJ, Norbeck DW, Leonard JM: Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemotherapy 1997; 41: 654-660.
5. Kumar GN, Dykstra J, Roberts EM, Jayanti VK, Hickman D, Uchic J, Yao Y, Surber B, Thomas S, Granneman R: Potent inhibiton of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab Dispos 1999; 27: 902-908.
6. Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, Kati W, Stewart K, Lal R, Hsu A, Betebenner D, Korneyeva M, Vasavanonda S, McDonald E, Saldivar A, Wideburg N, Chen X, Niu P, Park C, Jayanti V, Grabowski B, Granneman GR, Sun E, Japour AJ, Leonard JM, Plattner JJ, Norbeck DW: ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998; 42: 3218-3224.
7. Lal R, Hsu A, Granneman GR, El-Shourbagy T, Johnson M, Lam W, Japour A, Leonard J, Granneman GR, Sun E: Multiple dose safety, tolerability and pharmacokinetics of ABT-378 in combination with ritonavir. 5th CROI 1998, abstr. 647.
8. Bertz R, Lam W, Brun S, Kumar G, Fields C, Orth K, Jennings J, Hsu A, Granneman GR, Japour A, Sun E: Multiple-dose pharmacokinetics (PK) of ABT-378/ ritonavir (ABT-378/r) in HIV+ subjects. 39th ICAAC 1999; abstr. 327.
9. Benson CA, Deeks SG, Brun SC, Gulick RM, Eron JJ, Kessler HA, Murphy RL, Hicks C, King M, Wheeler D, Feinberg J, Stryker R, Sax PE, Riddler S, Thompson M, Real K, Hsu A, Kempf D, Japour AJ, Sun E: Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapin and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor experienced patients. J Infect Dis 2002; 185: 599-607.
10. Stryker R, Brun S, King M, Marsh T, Murphy R, Hicks C, Eron J, Thommes J, Gulick R, Glesby M, Thompson M, White C, Benson C, Albrecht M, Kessler H, Real K, Japour A, Perrin L, Sun E: ABT-378/ritonavir (ABT-378/r) in antiretroviral naive HIV+ patients: follow-up beyond 2 years and viral load suppression below 3 copies/ml. AIDS 2000; 14 (Suppl. 4): S30 poster 46.
11. Rockstroh J, Brun S, Sylte J, Xu Y, Clumeck N, Lazzarini A, Girard PM, Becker S, Telenti A, Bergmann F, Danner S, Ho D, Tubiana R, Carosi G, Bertz R, Hsu A, Kempf DJ, Sun E: ABT-378/ritonavir (ABT-378/r) and efavirenz: one year safety/efficacy evaluation in multiple PI experienced patients. AIDS 2000; 14 (Suppl. 4): S29 poster 43.
12. Murphy RL, Brun S, Hicks C, Eron JJ, Gulick R, King M, White AC, Benson C, Thompson M, Kessler HA, Hammer S, Bertz R, Hsu A, Japour A, Sun E: ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV 1 infection: 48-week results. AIDS 2001; 15: F2-F9.
13. Bernstein B, Kempf D, King M, Moseley J, Cernohous P, Gu K, Bauer E, Sun E: Absence of resistance to lopinavir/r (ABT-378/r) observed through 48 weeks of therapy in antiretroviral - naive subjects. 8th CROI 2001; abstr. 453.
14. Carrillo A, Stewart KD, Sham HL, Norbeck DW, Kohlbrenner WE, Leonard JM, Kempf DJ, Molla A: In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol 1998; 72: 7532-7541.
15. Kempf DJ, Isaacson DJ, King MS, Brun SC, Xu Y, Real K, Bernstein BM, Japour AJ, Sun E, Rode RA: Identification of genotypic changes in human Immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor loplnavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001; 75: 7462-7469.
16. 1993 revised classification system for HIV-infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41(RR-17): 1-19.
17. De Mendoza C, Matin-Caronero L, Barreiro P, Diaz B, Valencia E, Jimenez-Nacher I, Gallego O, Nunez M, Gonzalez-Lahoz J, Soriano V: Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families. HIV Clin Trials 2002; 3: 304-309.
18. Masquelier B, Breilh D, Neau D, Lawson-Ayayi S, Lavignolle V, Ragnaud JM, Dupon M, Morlat P, Dabis F, Fleury H, and the Groupe d'Epidemiologie Clinique du SIDA en Aquitaine: Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir- containing therapy in protease inhibitor-experienced patients. Antimicrob. Agents Chemother 2002; 46: 2926-2932.
19. Boffito M, Arnaudo I, Raiteri R, Bonora S, Sinicco A, Di Garbo A, Reynolds HE, Hoggard PG, Back DJ, Di Perri G: Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. AIDS 2002; 16: 2081-2083.
20. Tsuchiya K, Matsuoka S, Hachiya A, Yasuoka A, Tachikawa N, Kikuchi Y, Genka I, Teruya K, Kimura S, Oka S: Accumulation of lopinavir resistance-associated mutations over 3 years follow -up of patients on highly active antiretroviral therapy: implications in salvage therapy. AIDS 2001; 15: 1183-1184.